Your browser doesn't support javascript.
loading
Prognostic impact of fluorescent lymphography on gastric cancer.
Park, Sung Hyun; Kim, Ki-Yoon; Cho, Minah; Kim, Yoo Min; Kim, Hyoung-Il; Hyung, Woo Jin.
Afiliación
  • Park SH; Department of Surgery, Yonsei University College of Medicine.
  • Kim KY; Gastric Cancer Center, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea.
  • Cho M; Department of Surgery, Yonsei University College of Medicine.
  • Kim YM; Gastric Cancer Center, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea.
  • Kim HI; Department of Surgery, Yonsei University College of Medicine.
  • Hyung WJ; Gastric Cancer Center, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea.
Int J Surg ; 109(10): 2926-2933, 2023 Oct 01.
Article en En | MEDLINE | ID: mdl-37352518
ABSTRACT

BACKGROUND:

Fluorescent lymphography-guided lymphadenectomy (FL) for gastric cancer is gaining popularity. However, its impact on prognosis is not known. This study aimed to assess the prognostic impact of FL in gastric cancer patients. MATERIALS AND

METHODS:

This study retrospectively analyzed 5678 gastric cancer patients who underwent gastrectomy from 2013 to 2017. The survival was compared between the FLFL group and the conventional lymphadenectomy (non-FL group) using 11 propensity score matching after exclusion. Patients in the FL group underwent gastrectomy with systematic lymphadenectomy after endoscopic peritumoral injection of indocyanine green the day before surgery.

RESULTS:

After propensity score matching, the FL and non-FL groups each had 1064 patients with similar demographic and clinicopathological characteristics. All matched variables had a standardized mean difference under 0.1. The FL group showed a significantly higher number of retrieved lymph nodes (56.2±20.1) than the non-FL group (46.2±18.2, P <0.001). The FL group also had more stage III patients ( P= 0.044) than the non-FL group. The FL group demonstrated higher overall survival ( P= 0.038) and relapse-free survival ( P= 0.036) in stage III compared with the non-FL group. However, no significant differences in overall and relapse-free survival were observed between the two groups for stages I ( P= 0.420 and P= 0.120, respectively) and II ( P= 0.200 and P= 0.280, respectively).

CONCLUSION:

FL demonstrated a higher survival in stage III gastric cancer patients by the more accurate staging resulting from larger lymph node retrieval. Thus, given its potential to improve prognostication by enhancing staging accuracy, it is recommended as an option to consider the use of FL in clinical practice.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Linfografía Tipo de estudio: Prognostic_studies Idioma: En Revista: Int J Surg Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Linfografía Tipo de estudio: Prognostic_studies Idioma: En Revista: Int J Surg Año: 2023 Tipo del documento: Article